Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

• Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT.
• Early access launch of a completely reimagined Stelo app will define a new era of glucose tracking for all people not on insulin seeking better health.
• Acquisition of Nutrisense will strengthen Dexcom’s ability to provide personalized nutrition education and coaching to improve diabetes management and help further establish CGM as an effective tool for preventative care.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026.

“Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, expanding access and developing new CGM solutions to better support early-stage intervention and preventative care are top priorities,” said Jake Leach, president and CEO at Dexcom. “Through clinical research like the CONNECT study, upcoming launch of reimagined Stelo app and the acquisition of Nutrisense, Dexcom is building an even more accessible and connected ecosystem designed to help as many people as possible better understand their glucose health and manage it with real time insights, personalized support and coaching.”

CONNECT study will demonstrate Dexcom CGM benefits for adults with Type 2 diabetes not using insulin

Co-author of the CONNECT study, Thomas W. Martens, MD, from the International Diabetes Center, will present findings from the randomized controlled trial showcasing the clinical benefits of Dexcom CGM use by adults with Type 2 diabetes not on insulin therapy. This RCT study has the potential to have considerable impact to future standards of care for the Type 2 non-insulin using patient population¹. The presentation will take place on Saturday, June 6 at 1:45 p.m. CDT in the Ernest N. Morial Convention Center, La Nouvelle Orleans C (Level 2).

Reimagined Stelo app receives FDA clearance and will define a new era of glucose tracking for all people not on insulin seeking better health

On June 5, select Stelo users will be offered the opportunity for early access to a completely reimagined app experience, which received FDA clearance last month. Stelo will now provide all people not on insulin seeking better health a smarter, more intuitive way to understand their metabolism. The redesigned app will launch with a suite of new features including pattern recognition, proactive AI coaching and personalized daily and weekly summaries. These new features make it even easier for users to track and understand their body over time, revealing connections between glucose patterns and how they feel. The full rollout of the new Stelo app experience is expected later this summer.

Nutrisense acquisition will enhance nutrition capabilities within the Dexcom ecosystem

Dexcom has entered into an agreement to acquire Nutrisense, with the transaction anticipated to close in the coming weeks, subject to customary closing conditions and regulatory approvals. With this acquisition, Dexcom will further expand its ability to support users beyond glucose data alone by incorporating access to registered dietitians, personalized nutrition guidance and behavior-change support. The acquisition strengthens Dexcom’s ability to provide personal nutrition education and guidance linking food choices to glucose responses.

Together, these announcements at the ADA Scientific Sessions reflect Dexcom’s continued investment in evidence-based, technology-enabled solutions designed to expand access to CGM, support earlier intervention and offer more personalized diabetes and metabolic health management.

For a detailed overview of Dexcom’s presence at ADA this year, visit: dexcom.events/2026-ADA.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

Category: IR

^{1. Oser T, et al. CGM for Adults with Type 2 Diabetes Not on Insulin: The CONNECT Randomized Controlled Trial. Presented at ADA 2026.}